Articles related to BLOOD CANCERS
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
With more than 27,000 doses administered, CAR T-cell therapies represent a breakthrough in treating hematologic malignancies, though emerging reports of secondary T-cell cancers post-treatment highlight the importance of long-term patient monitoring and reporting.
Hematology/Oncology February 5th 2024
Exploring How CAR T-Cell Therapy May Help More Patients
Recent advances in CAR T-cell therapy show significant promise in treating both blood cancers and solid tumors, offering durable responses and extended survival rates for patients previously facing limited options.
Hematology/Oncology January 22nd 2024
“System Failures” After Acquisition Leave Cancer Patients in Limbo
Discover how system failures at Messino Cancer Centers have led to a critical decision impacting patient care. Learn more about this significant development and its implications for healthcare delivery.
Hematology/Oncology October 17th 2023
Highlights in Leukemia and Lymphoma
Uncover the potential of nivolumab and axicabtagene ciloleucel as they showcase promising results in the latest lymphoma trials, potentially reshaping the standard of care for these malignancies.
Hematology/Oncology July 25th 2023